Recent trends in microbially and/or enzymatically driven colon-specific drug delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 28, Issue 6, 2011, Pages 489-552

  Patel, Mayur M ^a   Amin, Avani F ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Biodegradable polymers; Colonic drug delivery; Enzymes; In vitro and in vivo evaluation; Polymeric drug delivery systems; Prodrugs

Indexed keywords

ALGINIC ACID; AMINO ACID; AMYLOSE; AZO COMPOUND; AZO REDUCTASE; BACTERIAL ENZYME; BALSALAZIDE; BIOPOLYMER; CARBON NANOTUBE; CHITOSAN; CHONDROITIN SULFATE; CYCLODEXTRIN; DEXTRIN; DEXTRO PHENYLALANINE; DRUG CARRIER; GUAR GUM; INULIN; KONJAC GLUCOMANNAN; MACROGOL; MANNAN; N NICOTINOYLGLYCYL 2 (5 FLUOROURACIL 1 YL) DEXTRO,LEVO GLYCINE; NUTRIOSE; PECTIN; PRODRUG; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHAN;

ANAEROBIC BACTERIUM; BACTERIAL FLORA; BIOCOMPATIBILITY; COLON; COLON ABSORPTION; COLON FLORA; COMPLEX FORMATION; CONJUGATION; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG PELLET; DRUG PENETRATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; ENZYME DEGRADATION; ENZYME PRODRUG THERAPY; FILM COATING; GAMMA SCINTIGRAPHY; GRAM POSITIVE BACTERIUM; HUMAN; HYDROGEL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO CULTURE; INTESTINE FUNCTION; LIPOPHILICITY; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; OSMOTIC PUMP; OXIDATION REDUCTION POTENTIAL; PARTITION COEFFICIENT; PH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH PH; TABLET DISINTEGRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER GASTROINTESTINAL TRACT;

EID: 82755166797     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i6.10     Document Type: Review

References (326)

1. Liu LS, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 2003;24:3333-3343.
2. Florence AT, Jani PU. Particulate delivery: the challenge of the oral route. In: Rolland A, editor. Pharmaceutical particulate carriers: therapeutic applications. New York: Marcel Dekker; 1993. p. 65-107.
3. Chen H, Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliv Rev. 1998;34:339-350.
4. Newsletter. Oral drug delivery. DrugDel.com. October 2002.
5. Sinha VR, Kumria R. Polysaccharides in colon-specifc drug delivery. Int J Pharm. 2001;224:19-38.
6. Vandamme TF, Lenourry A, Charrueau C, Chaumeil JC. The use of polysaccharides to target drugs to the colon. Carbohydr Polym. 2002;48:219-231.
7. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm Res. 1996;13:1760-1763.
8. Patel M, Shah T, Amin A. Therapeutic opportunities in colon specific drug delivery system. Crit Rev Ther Drug Carrier Syst. 2007;24:147-202.
9. Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for site-specifc drug delivery to the colon. J Pharm Pharmaceut Sci. 2007;10:86-128.
10. MacFarlane GT, Cummings JH, MacFarlane S, Gibson GR. Influence of retention time on degradation of pancreatic enzymes by colonic bacteria grown in 3-stage continuous culture system. J Appl Bacteriol. 1989;67:521-527.
11. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci. 2003;18:3-18.
12. Leopold CS. Coated dosage forms for colon-specific drug delivery. Pharm Sci Technol Today. 1999;2:197-204.
13. Leopold CS. Basic coating polymers for the colon specific drug delivery in infammatory bowel disease. Drug Dev Ind Pharm. 2000;26:1239-1246.
14. Reddy SN, Bazzocchi G, Chan S, Akashi K, Villanueva-Meyer J, Yanni G, Mena I, Snape WJ Jr. Colonic motility and transit in health and ulcerative colitis. Gastroenterology. 1991;101:1289-1297.
15. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon infuences stool weight in the irritable bowel syndrome. Gastro-enterology. 1992;102:102-108.
16. Yang L, James S, Chu Joseph A. Colon specifc drug delivery, new approaches and in vitro/ in vivo evaluation. Int J Pharm. 2002;235:1-15.
17. Rubinstein A. Natural polysaccharides as targeting tools of drugs to the human colon. Drug Dev Res. 2000;50:435-439.
18. Moore WEC, Holdeman LV. Discussion of current bacteriologic investigation of the relationships between intestinal fora, diet and colon cancer. Cancer Res. 1975;35:3418-3420.
19. Savage DC. Interactions between the host and its microbes. In: Clarke RTJ, Bauchop T, editors. Microbial Ecology of the Gut. New York: Academic Press; 1977. p. 277-310.
20. Simon GL, Gorbach SL. Intestinal fora in health and disease. Gastroenterology. 1984;86:174-193.
21. Gorbach SL, Plavt AG, Nahas L, Weinstein L. Studies of intestinal microfora. II. Microorganism of the small intestine and their relations to oral and fecal flora. Gastroenterology. 1967;53:856-867.
22. Gorbach SL, Levitan R. Intestinal flora in health and in gastrointestinal diseases. In: Glass GBJ, editor. Progress in Gastroenterology. New York: Grune and Stratton; 1970. p. 252-275.
23. Hill MJ, Drasar BS. The normal colonic bacterial fora. Gut. 1975;16:318-323.
24. Finegold SM, Sutter VL, Sugihara PT, Elder HA, Lehman SM, Phillips RL. Fecal micro-bial fora in Seventh Day Adventist population and control subjects. Am J Clin Nutr. 1977;30:1781-1792.
25. Moore WEC, Holdeman LV. Human fecal flora: the normal flora of twenty Japanese- Hawaiians. Appl Microbiol. 1974;27:961-979.
26. Hawksworth G, Drasar BS, Hill MJ. Intestinal bacteria and hydrolysis of glycosidic bonds. J Med Microbiol. 1971;4:451-459.
27. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev. 1973;25:451-523.
28. Faigle JW. Drug metabolism in the colon wall and lumen. In: Bieck PR, editor. Colonic drug absorption and metabolism. New York: Marcel Dekker; 1993. p. 29-54.
29. Jung Y, Kim YM. What should be considered on design of a colon-specifc prodrug? Exp Opin Drug Deliv. 2010;7:245-258.
30. McBee RH. Metabolic contributions of the cecal fora. Am J Clin Nutr. 1970;23:1514-1518.
31. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos. 1990;11:465-475.
32. MacFarlane GT, Hay S, Gibson GR. Infuence of mucin on glycosidase, protease and ary-lamidase activities of human gut bacteria grown in a 3-stage continuous culture system. J Appl Bacteriol. 1989;66:407-417.
33. Stirrup V, Evans DF, Ledingham S, Thomas M, Pye G, Hardcastle JD. Redox potential measurement in the gastrointestinal tract in man. Proceedings of the World Congress of Gastroen-terology, Digestive Endoscopy, and Coloproctology; 1990 August 26-31; Sydney, Australia.
34. Wilding IR, Davis SS, O'Hagan OT. Targeting of drugs and vaccines to the gut. Pharmacol Ther. 1994;62:97-124.
35. Grim Y, Kopecek J. Bioadhesive water-soluble polymeric drug carriers for site-specifc oral drug delivery. Synthesis, characterization and release of 5-aminosalicylic acid by Streptococcus faecium in vitro. New Polymer Mater. 1991;3:49-59.
36. Hovgaard L, Brondsted H. Current applications of polysaccharides in colon targeting. Crit Rev Ther Drug Carrier Syst. 1996;13:185-223.
37. Knapczyk J, Krowczynski L, Pawlik B, Liber Z. Pharmaceutical dosage forms with chito-san. In: Skjak-Braek G, Anthonsen T, Sandford P, editors. Chitin and Chitosan: Sources: Chemistry, Biochemistry, Physical Properties and Applications. London: Elsevier; 1984. p. 665-669.
38. Hirano S, Seino H, Akiyama Y, Nonaka I. Chitosan: a biocompatible material for oral and intravenous administration. In: Gebelein CG, Dunn RL, editors. Progress in Biomedical Polymers. New York: Plenum Press; 1990. p. 283-290.
39. Struszczyk H, Wawro D, Niekraszewicz A. Biodegradability of chitosan fbres. In: Brine CJ, Sandford PA, Zikakis JP, editors. Advances in Chitin and Chitosan. London: Elsevier; 1991. p. 580-585.
40. Jain SK, Jain A, Gupta Y, Ahirwar M. Design and development of hydrogel beads for targeted drug delivery to the colon. AAPS PharmSciTech. 2007;8:E34-E41.
41. Zhao XL, Li KX, Zhao XF, Pang DH, Chen DW. Study on colon-specifc 5-FU pH-enzyme Di-dependent chitosan microspheres. Chem Pharm Bull. 2008;56:963-968.
42. Umadevi SK, Thiruganesh R, Suresh S, Reddy KB. Formulation and evaluation of chito-san microspheres of aceclofenac for colon-targeted drug delivery. Biopharm Drug Dispos. 2010;31:407-427.
43. Nunthanid J, Huanbutta K, Luangtana-anan M, Sriamornsak P, Limmatvapirat S, Puttipipat-khachorn S. Development of time-, pH-, and enzyme-controlled colonic drug delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose. Eur J Pharm Biopharm. 2008;68:253-259.
44. Nunthanid J, Luangtana-anan M, Sriamornsak P, Limmatvapirat S, Huanbutta K, Puttipi-patkhachorn S. Use of spray-dried chitosan acetate and ethylcellulose as compression coats for colonic drug delivery: effect of swelling on triggering in vitro drug release. Eur J Pharm Biopharm. 2009;71:356-361.
45. Kaur K, Kim K. Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery. Int J Pharm. 2009;366:140-148.
46. Liu H, Yang XG, Nie SF, Wei LL, Zhou LL, Liu H, Tang R, Pan WS. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation. Int J Pharm. 2007;332:115-124.
47. Onishi H, Oosegi T, Machida Y, McGinity JW. Preparation and in vitro evaluation of chito-san microspheres containing prednisolone: comparison of simple and conjugate microsphe-res. Drug Dev Ind Pharm. 2005;31:597-605.
48. Oosegi T, Onishi H, Machida Y. Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Pharm Biopharm. 2008;68:260-266.
49. Oosegi T, Onishi H, Machida Y. Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int J Pharm. 2008;348:80-88.
50. Onishi H, Oosegi T, Machida Y. Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm. 2008;358:296-302.
51. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Del Rev. 2001;50(Suppl 1):S91-S101.
52. Curti E, de Britto D, Campana-Filho SP. Methylation of chitosan with iodomethane: effect of reaction conditions on chemoselectivity and degree of substitution. Macromol Biosci. 2003;3:571-576.
53. Mao S, Bakowsky U, Kissel T. Self assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J Pharm Sci. 2006;95:1035-1048.
54. Bayat A, Dorkoosh FA, Dehpour AR, Moezi L, Larijani B, Junginger HE, Rafee-Tehrani M. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm. 2008;356:259-266.
55. Wei H, Li-Fang F, Bai X, Chun-Lei L, Qing D, Yong-Zhen C, De-Ying C. An investigation into the characteristics of chitosan/Kollicoat SR30D free flms for colonic drug delivery. Eur J Pharm Biopharm. 2009;72:266-274.
56. Fan LF, He W, Chang YZ, Xiang B, Du Q, Wang F, Qin M, Cao DY. Studies of chitosan/Kol-licoat SR 30D film-coated tablets for colonic drug delivery. Int J Pharm. 2009;375:8-15.
57. Wei H, Li-Fang F, Min B, Yong-Zhen C, Bai X, Qing D, Feng W, Min Q, De-Ying C. Chi-tosan/Kollicoat SR 30D film-coated pellets of aminosalicylates for colonic drug delivery. J Pharm Sci. 2010;99:186-195.
58. McConnell EL, Murdan S, Basit AW. An investigation into the digestion of chitosan (non-crosslinked and crosslinked) by human colonic bacteria. J Pharm Sci. 2008;97:3820-3829.
59. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.
60. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277:4585-4588.
61. Turley EA, Belch AJ, Poppema S, Pilarski LM. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood. 1993;81:446-453.
62. Bourguignon LYW, Zhu HB, Shao LJ, Chen YW. CD44 interaction with Tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275:1829-1838.
63. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, Niimi A, Ueda M, Kimata K. Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res. 1999;90:987-992.
64. Wang C, Tammi M, Guo H, Tammi R. Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol. 1996;148:12-18.
65. Samuelsson C, Gustafson S. Studies on the interaction between hyaluronan and a rat colon cancer cell line. Glycoconj J. 1998;15:169-175.
66. Bel MK, Weichert W, Well KC, Schmitt WD, Lautenschlager C, Hauptmann S. Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcino-mas and linked to patient prognosis. Virchows Arch. 2004;445:456-464.
67. Culty M, Shizari M, Thompson EW, Underhill CB. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol. 1994;160:275-286.
68. Hua Q, Knudson CB, Knudson W. Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J Cell Sci. 1993;106:365-375.
69. Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparti-cles for colon tumors. Eur J Pharm Sci. 2008;35:404-416.
70. Jain A, Jain SK, Ganesh N, Barve J, Beg AM. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedi-cine. 2010;6:179-190.
71. Tuǧcu-Demiröz F, Acartürk F, Takka S, Konuş-Boyunaǧa O. In-vitro and in-vivo evaluation of mesalazine-guar gum matrix tablets for colonic drug delivery. J Drug Target. 2004;12:105-112.
72. Krishnaiah YS, Veer Raju P, Dinesh Kumar B, Bhaskar P, Satyanarayana V. Development of colon targeted drug delivery systems for mebendazole. J Control Releas. 2001;77:87-95.
73. Krishnaiah YS, Satyanarayana V, Kumar BD, Karthikeyan RS. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J Drug Target. 2002;10:247-254.
74. Durig T, Fassihi R. Guar-based monolithic matrix systems: Effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. J Controlled Rel. 2002;80:45-56.
75. Ji C, Xu H, Wu W. In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS 30D coated colon targeted pellets of indomethacin. J Drug Target. 2007;15:123-131.
76. Ji CM, Xu HN, Wu W. Guar gum as potential flm coating material for colon-specifc delivery of fuorouracil. J Biomater Appl. 2009;23:311-329.
77. Lai H, Lin K, Zhang W, Zhang Z, Jie L, Wu Y, He Q. Development of pH- and enzyme-controlled, colon-targeted, pulsed delivery system of a poorly water-soluble drug: preparation and in vitro evaluation. Drug Dev Ind Pharm. 2010;36:81-92.
78. Kumar P, Singh S, Mishra B. Colon targeted delivery systems of metronidazole based on osmotic technology: development and evaluation. Chem Pharm Bull. 2008;56:1234-1242.
79. Elias EJ, Anil S, Ahmad S, Daud A. Colon targeted curcumin delivery using guar gum. Nat Prod Commun. 2010;5:915-918.
80. Werch SC, Ivy AC. On the fate of ingested pectin. Am J Digest Dis. 1941;8:101-105.
81. Salyers AA, Vercellotti JR, West SEH, Wilkins TD. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol. 1977;33:319-322.
82. Rubinstein A, Radai R. Pectin salt as a colonic drug delivery system. Proc Int Symp Control Rel Bioact Mater. 1991;18:221-222.
83. Wei H, Qing D, De-Ying C, Bai X, Fanli-Fang. Pectin/ethylcellulose as film coatings for colon-specifc drug delivery: preparation and in vitro evaluation using 5-fuorouracil pellets. PDA J Pharm Sci Technol. 2007;61:121-130.
84. He W, Du Q, Cao DY, Xiang B, Fan LF. Study on colon-specific pectin/ethylcellulose flm-coated 5-fuorouracil pellets in rats. Int J Pharm. 2008;348:35-45.
85. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. In vitro and in vivo studies of pectin/ethylcellulose flm coated pellets of 5-fuorouracil for colonic targeting. J Pharm Pharmcol. 2008;60:35-44.
86. Wei H, Li-Fang F, Yong-Zhen C, Bai X, Qing D, Min B, Feng W, Min Q, De-Ying C. Pectin/ Kollicoat SR30D isolated films for colonic delivery [I]: a comparison of normal and colitis-induced models to assess the efficiency of microbially triggered drug delivery. J Pharm Pharmacol. 2009;61:167-176.
87. Ugurlu T, Turkoglu M, Gurer US, Akarsu BG. Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur J Pharm Biopharm. 2007;67:202-210.
88. Hodges LA, Connolly SM, Band J, O'Mahony B, Ugurlu T, Turkoglu M, Wilson CG, Stevens HN. Scintigraphic evaluation of colon targeting pectin-HPMC tablets in healthy volunteers. Int J Pharm. 2009;370:144-150.
89. Yehia SA, Elshafeey AH, Sayed I, Shehata AH. Optimization of budesonide compression-coated tablets for colonic delivery. AAPS PharmSciTech. 2009;10:147-157.
90. Sriamornsak P. Effect of calcium concentration, hardening agent and drying condition on release characteristics of oral proteins from calcium pectinate gel beads. Eur J Pharm Sci. 1999;8:221-227.
91. Maestrelli F, Cirri M, Corti G, Mennini N, Mura P. Development of enteric coated calcium pectinate microspheres intended for colonic drug delivery. Eur J Pharm Biopharm. 2008;69:508-518.
92. Rubinstein A, Radai R. In vitro and in vivo analysis of colon specifcity of calcium pectinate formulations. Eur J Pharm Biopharm. 1995;41:291-295.
93. Dupuis G, Chambin O, Génelot C, Champion D, Pourcelot Y. Colonic drug delivery: infu-ence of crosslinking agent on pectin beads properties and role of the shell capsule type. Drug Dev Ind Pharm. 2006;32:847-855.
94. Semde R, Amighi K, Devleeschouwe MJ, Moes AJ. Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate. Int J Pharm. 2000;197:169-179.
95. Chambin O, Dupuis G, Champion D, Voilley A, Pourcelot Y. Colon-specific drug delivery: Infuence of solution reticulation properties upon pectin beads performance. Int J Pharm. 2006;321:86-93.
96. Atyabi F, Majzoob S, Iman M, Salehi M, Dorkoosh F. In vitro evaluation and modifcation of pectinate gel beads containing trimethyl chitosan as a multi-particulate system for delivery of water-soluble macromolecules to colon. Carbohydrate Polym. 2005;61:39-51.
97. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15:1326-1331.
98. Paul W, Sharma CP. Chitosan, a drug carrier for the 21st century. STP Pharma Sci. 2000;10:5-22.
99. Marudova M, MacDougall AJ, Ring SG. Pectin-chitosan interactions and gel formation. Carbohydr Res. 2004;339:1933-1939.
100. Marudova M, Lang S, Brownsey GJ, Ring SG. Pectin-chitosan multilayer formation. Car-bohydr Res. 2005;340:2144-2149.
101. Fernandez-Hervas MJ, Fell JT. Pectin/chitosan mixtures as coatings for colon-specific drug delivery: an in vitro evaluation. Int J Pharm. 1998;169:115-119.
102. Munjeri O, Collett JH, Fell JT. Hydrogel beads based on amidated pectins for colon-specifc drug delivery: the role of chitosan in modifying drug release. J Controlled Rel. 1997;46:273-278.
103. Ofori-Kwakye K, Fell JT. Biphasic drug release: the permeability of films containing pectin, chitosan and HPMC. Int J Pharm. 2001;226:139-145.
104. Chang KLB, Lin J. Swelling behavior and the release of protein from chitosan-pectin composite particles. Carbohydrate Polym. 2000;43:163-169.
105. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P. Microspheres for colonic delivery of ketoprofen-hydroxypropyl-β-cyclodextrin complex. Eur J Pharm Sci. 2008;34:1-11.
106. Das S, Ng KY. Resveratrol-loaded calcium-pectinate beads: Effects of formulation parameters on drug release and bead characteristics. J Pharm Sci. 2010;99:840-860.
107. Das S, Ng KY. Colon-specific delivery of resveratrol: Optimization of multi-particulate calcium-pectinate carrier. Int J Pharm. 2010;385:20-28.
108. Das S, Ng KY. Impact of glutaraldehyde on in vivo colon-specifc release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci. 2010;99:4903-4916.
109. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragit-coated pectin microspheres of 5-fuorouracil for colon targeting. AAPS PharmSciTech. 2007;8:E87-E93.
110. Vaidya A, Jain A, Khare P, Agrawal RK, Jain SK. Metronidazole loaded pectin microsphe-res for colon targeting. J Pharm Sci. 2009;98:4229-4236.
111. Fude C, Lei Y, Jie J, Hongze P, Wenhui L, Dongmei C. Preparation and in vitro evaluation of pH, time-based and enzyme-degradable pellets for colonic drug delivery. Drug Dev Ind Pharm. 2007;33:999-1007.
112. Bigucci F, Luppi B, Monaco L, Cerchiara T, Zecchi V. Pectin-based microspheres for colon-specifc delivery of vancomycin. J Pharm Pharmacol. 2009;61:41-46.
113. Perera G, Barthelmes J, Bernkop-Schnürch A. Novel pectin-4-aminothiophenole conjugate microparticles for colon-specific drug delivery. J Controlled Rel. 2010;145:240-246.
114. Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, Ring SG, Stockham M, Allwood MC. Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Controlled Rel. 1996;38:75-84.
115. Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, Ring SG, Stockham M, Allwood MC. Amylose as a coating for drug delivery to the colon: Preparation and in vitro evaluation using glucose pellets. J Controlled Rel. 1996;38:85-94.
116. Wilson PJ, Basit AW. Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets. Int J Pharm. 2005;300:89-94.
117. Cummings JH, Milojevic S, Harding M, Coward WA, Gibson GR, Botham RL, Ring SG, Wraight EP, Stockham MA, Alwood MC, Newton JM. In vivo studies of amylose- and ethylcellulose-coated [13C] glucose microspheres as a model for drug delivery to the colon. J Controlled Rel. 1996;40:123-131.
118. Tuleu C, Basit AW, Waddington WA, Ell PJ, Newton JM. Colonic delivery of 4-aminosa-licylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules. Aliment Pharmacol Ther. 2002;16:1771-1779.
119. Available from: http://www.alizyme.com/alizyme/products/colalpred/
120. McConnell EL, Short MD, Basit AW. An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Controlled Rel. 2008;130:154-160.
121. Basit AW, Short MD, McConnell EL. Microbiota-triggered colonic delivery: robustness of the polysaccharide approach in the fed state in man. J Drug Target. 2009;17:64-71.
122. Freire AC, Fertig CC, Podczeck F, Veiga F, Sousa J. Starch based coatings for colonic spe-cifc drug delivery: Part I: the influence of heat treatment on the physicochemical properties of high-amylose maize starches. Eur J Pharm Biopharm. 2009;72:574-586.
123. Freire C, Podczeck F, Veiga F, Sousa J. Starch-based coatings for colon-specific delivery. Part II: physicochemical properties and in vitro drug release from high amylose maize starch films. Eur J Pharm Biopharm. 2009;72:587-594.
124. Freire C, Podczeck F, Ferreira D, Veiga F, Sousa J, Pena A. Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery. J Pharm Pharmacol. 2010;62:55-61.
125. Vervoort L, Kinget R. In vitro degradation by colonic bacteria of insulin HP incorporated in Eudragit films. Int J Pharm. 1996;129:185-190.
126. Akhgari A, Farahmand F, Afrasiabi Garekani H, Sadeghi F, Vandamme TF. Permeability and swelling studies on free films containing insulin in combination with different polymet-hacrylates aimed for colonic drug delivery. Eur J Pharm Sci. 2006;28:307-314.
127. Mandracchia D, Denora N, Franco M, Pitarresi G, Giammona G, Trapani G. New biodegradable hydrogels based on inulin and α,β-Polyaspartylhydrazide designed for colo-nic drug delivery: In vitro release of glutathione and oxytocin. J Biomater Sci Polym Ed. 2011;22:313-328.
128. Pitarresi G, Tripodo G, Calabrese R, Craparo EF, Licciardi M, Giammona G. Hydrogels for potential colon drug release by thiol-ene conjugate addition of a new insulin derivative. Macromol Biosci. 2008;8:891-902.
129. Kotagale N, Maniyar M, Somvanshi S, Umekar M, Patel CJ. Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine. Pharm Dev Technol. 2010;15:431-437.
130. Tripodo G, Pitarresi G, Cavallaro G, Palumbo FS, Giammona G. Controlled release of IgG by novel UV induced polysaccharide/poly(amino acid) hydrogels. Macromol Biosci. 2009;9:393-401.
131. Rubinstein A, Nakar D, Sintov A. Chondroitin sulphate: A potential biodegradable carrier for colon-specific drug delivery. Int J Pharm. 1992;84:141-150.
132. Rubinstein A, Nakar D, Sintov A. Colonic drug delivery: enhanced release of indomethacin from crosslinked chondroitin matrix in rat cecal content. Pharm Res. 1992;9:276-278.
133. Sintov A, Di-Capua N, Rubinstein A. Crosslinked chondroitin sulphate: characterization for drug delivery purposes. Biomaterials. 1995;6:473-478.
134. Kaur G, Rana V, Jain S, Tiwary AK. Colon delivery of budesonide: evaluation of chitosan-chondroitin sulfate interpolymer complex. AAPS PharmSciTech. 2010;11:36-45.
135. Amrutkar JR, Gattani SG. Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS PharmSciTech. 2009;10:670-677.
136. Wang L, Gu Y, Su Z, Ma G. Preparation and improvement of release behavior of chitosan microspheres containing insulin. Int J Pharm. 2006;311:187-195.
137. Ribeiro AJ, Silva C, Ferreira D, Veiga F. Chitosan-reinforced alginate microspheres obtained through the emulsifcation/internal gelation technique. Eur J Pharm Sci. 2005;25:31-40.
138. Colonna C, Conti B, Perugini P, Pavanetto F, Modena T, Dorati R, Genta I. Chitosan glu-tamate nanoparticles for protein delivery: Development and effect on prolidase stability. J Microencapsulation. 2007;24:553-564.
139. Perugini P, Maculotti K, Conti B, Modena T, Pavanetto F, Muzzarelli RAA, Castelli F, Genta I. Chitosan-oxychitin microspheres for oral administration of peptides. 29th Annual Meeting of the Controlled Release Society; 2002 July 20-25; Seoul, Korea.
140. Xing L, Dawei C, Liping X, Rongqing Z. Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. J Controlled Rel. 2003;93:293-300.
141. Sui W, Huang L, Wang J, Bo Q. Preparation and properties of chitosan chondroitin sulphate complex microcapsules. Colloids Surf B Biointerfaces. 2008;65:69-73.
142. Maculotti K, Tira EM, Sonaggere M, Perugini P, Conti B, Modena T, Pavanetto F. In vitro evaluation of chondroitin sulphate-chitosan microspheres as carrier for the delivery of proteins. J Microencapsul. 2009;26:535-543.
143. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of infam-matory bowel disease. J Pharmacol Exp Ther. 2001;299:775-781.
144. Lamprecht A, Schafer U, Lehr CM. Size-dependant bioadhesion of micro-and nanoparticu-late carriers to the inflamed colonic mucosa. Pharm Res. 2001;18:788-793.
145. Bernkop-Schnurch A, Kast EC, Richter FM. Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J Controlled Rel. 2001;71:277-285.
146. Wittaya-areekul S, Kruenate J, Prahsarn C. Preparation and in vitro evaluation of mucoad-hesive properties of alginate/chitosan microparticles containing prednisolone. Int J Pharm. 2006;312:113-8.
147. Mladenovska K, Raicki RS, Janevik EI, Ristoski T, Pavlova MJ, Kavrakovski Z, Dodov MG, Goracinova K. Colon-specifc delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. Int J Pharm. 2007;342:124-136.
148. Simonoska Crcarevska M, Glavas Dodov M, Goracinova K. Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the infamed colonic mucosa. Eur J Pharm Biopharm. 2008;68:565-578.
149. Crcarevska MS, Dodov MG, Petrusevska G, Gjorgoski I, Goracinova K. Bioeffcacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis. J Drug Target. 2009;17:788-802.
150. Xu Y, Zhan C, Fan L, Wang L, Zheng H. Preparation of dual crosslinked alginate-chitosan blend gel beads and in vitro controlled release in oral site-specifc drug delivery system. Int J Pharm. 2007;336:329-337.
151. Tapia C, Molina S, Diaz A, Abugoch L, Diaz-Dosque M, Valenzuela F, Yazdani-Pedram M. The effect of chitosan as internal or external coating on the 5-ASA release from calcium alginate microparticles. AAPS PharmSciTech. 2010;11:1294-1305.
152. Moustafne RI, Salachova AR, Frolova ES, Kemenova VA, Van den Mooter G. Interpoly-electrolyte complexes of Eudragit E PO with sodium alginate as potential carriers for colo-nic drug delivery: monitoring of structural transformation and composition changes during swellability and release evaluating. Drug Dev Ind Pharm. 2009;35:1439-1451.
153. Hiorth M, Skøien T, Sande SA. Immersion coating of pellet cores consisting of chitosan and calcium intended for colon drug delivery. Eur J Pharm Biopharm. 2010;75:245-253.
154. Zhang X, Hui Z, Wan D, Huang H, Huang J, Yuan H, Yu J. Alginate microsphere flled with carbon nanotube as drug carrier. Int J Biol Macromol. 2010;47:389-395.
155. Asghar LF, Chure CB, Chandran S. Colon specific delivery of indomethacin: effect of incorporating pH sensitive polymers in xanthan gum matrix bases. AAPS PharmSciTech. 2009;10:418-429.
156. Sinha VR, Kumria R. Polysaccharide matrices for microbially triggered drug delivery to the colon. Drug Dev Ind Pharm. 2004;30:143-150.
157. Krishnaiah YSR, Satyanarayana S, Rama Prasad YV, Narasimha RS. Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm. 1998;171:137-146.
158. Talukdar MM, Rombaut P, Kinget R. The release mechanism of an oral controlled-release delivery system for indomethacin. Pharm Dev Technol. 1998;3:1-6.
159. Yeole PG, Galgatte UC, Babla IB, Nakhat PD. Design and evaluation of xanthan gum-based sustained release matrix tablets of diclofenac sodium. Indian J Pharm Sci. 2006;68:185-189.
160. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Development of polysaccharide-based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm. 2007;33:255-264.
161. Sinha VR, Singh A, Singh S, Bhinge JR. Compression coated systems for colonic delivery of 5-fuorouracil. J Pharm Pharmacol. 2007;59:359-365.
162. Wang K, Fan J, Liu Y, He Z. Konjac glucomannan and xanthan gum as compression coat for colonic drug delivery: experimental and theoretical evaluations. Front Chem Eng China. 2010;4:102-108.
163. Wang K, He ZM. Alginate-konjac glucomannan-chitosan beads as controlled release matrix. Int J Pharm. 2002;244:117-126.
164. Liu MM, Fan JY, Wang K, He ZM. Synthesis, characterization, and evaluation of phosphated crosslinked konjac glucomannan hydrogels for colon-targeted drug delivery. Drug Delivery. 2007;14:397-402.
165. Sinha VR, Mittal BR, Bhutani KK, Kumria R. Colonic drug delivery of 5-fuorouracil: an in vitro evaluation. Int J Pharm. 2004;269:101-108.
166. Fan JY, Wang K, Liu MM, He ZM. In vitro evaluations of konjac glucomannan and xan-than gum mixture as the sustained release material of matrix tablet. Carbohyd Polym. 2008;73:241-247.
167. Paradossi G, Chiessi E, Barbiroli A, Fessas D. Xanthan and glucomannan mixtures: syner-gistic interactions and gelation. Biomacromolecules. 2002;3:498-504.
168. Alvarez-Mancenido F, Landin M, Martinez-Pacheco R. Konjac glucomannan/xanthan gum enzyme sensitive binary mixtures for colonic drug delivery. Eur J Pharm Biopharm. 2008;69:573-581.
169. Zhang Y, Ling CS, Hou SX. Study on release mechanism of berberine hydrochloride-loaded carboxymethyl konjac glucomannan pellets for colonic delivery. Zhongguo Zhong Yao Za Zhi. 2008;33:23-26.
170. Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Dubreuil L, Desreumaux P, Siep-mann J. Colon targeting with bacteria-sensitive films adapted to the disease state. Eur J Pharm Biopharm. 2009;73:74-81.
171. Wils D, Scheuplein RJ, Deremaux L, Looten PH. Safety profle of a food dextrin: acute oral, 90-day rat feeding and mutagenicity studies. Food Chem Toxicol. 2008;46:3254-3261.
172. Pasman WJ, Wils D, Saniez MH, Kardinaal AFM. Long-term gastrointestinal tolerance of Nutriose FB in healthy men. Eur J Clin Nutr. 2006;60:1024-1034.
173. Lefranc-Millot C, Wils D, Neut C, Saniez MH. Effects of a soluble fiber, with excellent tolerance, Nutriose FB 06, on the gut ecosystem: a review. Dietary Fiber Congress; 2006 June 12-14; Helsinki, Finland.
174. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. Am J Clin Nutr. 2001;73:415-420.
175. Macfarlane S, Macfarlane GT, Cummings JH. Prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther. 2006;24:701-714.
176. Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Desreumaux P, Siepmann J. Novel polymeric flm coating for colon targeting: how to adjust desired membrane properties. Int J Pharm. 2009;371:64-70.
177. Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Flament MP, Dubreuil L, Desreu-maux P, Siepmann J. Novel polymeric flm coatings for colon targeting: Drug release from coated pellets. Eur J Pharm Sci. 2009;37:427-433.
178. Hu L. Prodrug approaches to drug delivery. In: Wang B, Siahaan T, Soltero R, editors. Drug delivery: Principles and application. New Jersey: John Wiley and Sons; 2005. p. 125-165.
179. Ryde EM. Low molecular weight azo compounds. In: Friend DR, editor. Oral Colon speci-fc drug delivery. Florida: CRC Press; 1992. p. 143-152.
180. Azad Khan AK, Guthrie G, Johnston HH, Truelove SC, Williamson DH. Tissue and bacterial splitting of sulphasalazine. Clin Sci 1983;64:349-354.
181. Chung KT, Fulk GE, Egan M. Reduction of azo dyes by intestinal anaerobes. Appl Environ Microbiol. 1978;35:558-562.
182. Dubin P, Wright KL. Reduction of azo food dyes in cultures of Proteus vulgaris. Xenobio-tica. 1975;5:563-571.
183. Schroder H, Johansson AK. Redox potential in caecal contents of the rat and azo reduction of salicyl-azo-sulphapyridine. Xenobiotica. 1973;3:233-246.
184. Hartman CP, Fulk GE, Andrews AW. Azo reduction of trypan blue to a known carcinogen by a cell-free extract of a human intestinal anaerobe. Mutat Res. 1978;58:125-132.
185. Kopecek J, Kopeckova P. N-(2-hydroxypropyl) methacrylamide co-polymers for colon specifc drug delivery. In: Friend DR, editor. Oral Colon specifc drug delivery. Florida: CRC Press; 1992. p. 189-211.
186. Saffran M. Oral colon specifc drug delivery with emphasis on insulin. In: Friend DR, editor. Oral Colon specifc drug delivery. Florida: CRC Press; 1992. p. 115-142.
187. Svarts S. Salazopyrin, a new sulfanilamide preparation. Acta Med Scan. 1942;110:577-598.
188. Baron JH, Connell AM, Lennard-Jones JE, Jones FA. Sulphasalazine and salicylazosulpha-dimidine in ulcerative colitis. Lancet. 1962;1:1094-1096.
189. Peppercorn MA, Goldman PJ. The role of intestinal bacteria in the metabolism of salicyla-zosulfapyridine. J Pharmacol Exper Ther. 1972;181:555-562.
190. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci. 2003;6:33-66.
191. Raff R, Franklin W, Cerniglia CE. Azoreductase activity of anaerobic bacteria isolated from human intestinal microfora. Appl Environ Microbiol. 1990;56:2146-2151.
192. Raff R, Franklin W, Hefich RH, Cerniglia CE. Reduction of nitroaromatic compounds by anaerobic bacteria isolated from the human intestinal tract. Appl Environ Microbiol. 1991;57:962-968.
193. Walker R, Ryan AJ. Some molecular parameters infuencing rate of reduction of azo compounds by intestinal microfora. Xenobiotica. 1971;1:483-486.
194. Azad Khan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulfasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982;13:523-528.
195. Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate a potential therapeutic agent for ulcerative colitis. Gut. 1982;23:1081-1087.
196. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983;28:609-615.
197. Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scand J Gastroenterol. 1988;23:40-44.
198. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Gut. 1988;29:835-837.
199. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double blind, dose-ranging clinical trial. Gastroenterology. 1987;93:1255-1262.
200. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcera-tive colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986;90:1024-1030.
201. Sandberg-Gertzen H, Jarnerot G, Tysk C. Long-term treatment with olsalazine for ulcera-tive colitis: safety and relapse prevention: follow-up study. Scand J Gastroenterol Suppl. 1988;148:48-50.
202. McIntyre PB, Rodrigues CA, Lennard-Jones JE, Barrison IG, Walker JG, Baron JH, Thornton PC. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double blind comparison with sulphasalazine. Alim Pharmacol Ther. 1988;2:237-243.
203. Fleig WE, Laudage G, Sommer H, Wellman W, Stange EF, Riemann J. Prospective, randomized, double blind comparison of bensalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion. 1988;40:173-180.
204. Bartalsky A. Salicylazobenzoic acid in ulcerative colitis. Lancet. 1982;1:960-962.
205. Friend DR. New oral delivery systems for treatment of infammatory bowel disease. Adv Drug Del Rev. 2005;57:247-265.
206. Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimer conjugates for colonic delivery of 5-aminosalicylic acid. J Controlled Rel. 2003;88:1-9.
207. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. Dendrimers: Relationship between structure and biocompatibility in vitro and preliminary studies on the biodistribution of 125I-labelled PAMAM dendrimers in vivo. J Controlled Rel. 2000;65:133-148.
208. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. Anionic PAMAM dendri-mers rapidly cross adult rat intestine in vitro: a potential oral delivery system. Pharm Res. 2000;17:991-998.
209. Canevari M, Castagliuolo I, Brun P, Cardin M, Schiavon M, Pasut G, Veronese FM. Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery. Int J Pharm. 2009;368:171-177.
210. Jain A, Gupta Y, Jain SK. Azo chemistry and its potential for colonic delivery. Crit Rev Ther Drug Carrier Syst. 2006;23:349-400.
211. Nakamura J, Kido M, Nishida K, Sasaki H. Hydrolysis of salicylic acid tyrosine salicylic acid-methionine prodrugs in rabbits. Int J Pharm. 1992;87:59-66.
212. Nakamura J, Tagami C, Nishida K, Sasaki H. Unequal hydrolysis of salicylic acid-D-alanine and salicylic acid-L-alanine conjugate in rabbit intestinal microorganisms. Chem Pharm Bull. 1992;40:547-549.
213. Nakamura J, Asai P, Nishida K, Sasaki H. A novel prodrug of salicylic acid, salicylic acid-glutamic acid conjugate utilizing hydrolysis in rabbit intestinal microorganisms. Chem Pharm Bull. 1992;40:2164-2168.
214. Nakamura J, Kido M, Nishida K, Sasaki H. Effect of oral pretreatment with antibiotics on the hydrolysis of salicylic acid tyrosine and salicylic acid methionine prodrugs in rabbit intestinal microorganisms. Chem Pharm Bull. 1992;40:2572-2576.
215. Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: Synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzene sulfonic acid-induced colitis in rats. Bioorg Med Chem. 2007;15:4903-4909.
216. Dhaneshwar SS, Kandpal M, Vadnerkar G, Rathi B, Kadam SS. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specifc drug delivery in infammatory bowel disease. Eur J Med Chem. 2007;42:885-890.
217. Dhaneshwar SS, Gairola N, Kandpal M, Bhatt L, Vadnerkar G, Kadam SS. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosali-cylic acid with D-phenylalanine for colon specifc drug delivery in infammatory bowel disease. Bioorg Med Chem Lett. 2007;17:1897-1902.
218. Meyers BE, Moonka DK, Davis RH. The effect of selected amino acids on gelatin-induced infammation in adult male mice. Infammation. 1979;3:225-234.
219. Lee JS, Jung YJ, Kim YM. Synthesis and evaluation of N-acyl-2-(5-fuorouracil-1-yl)-D, L-glycine as a colon-specifc prodrug of 5-fuorouracil. J Pharm Sci. 2001;90:1787-1794.
220. Dhaneshwar SS, Chail M, Patil M, Naqvi S, Vadnerkar G. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur J Med Chem. 2009;44:131-142.
221. Lee J, Rho J, Yang Y, Kong H, Jung Y, Kim Y. Synthesis and in vitro evaluation of N-nico-tinoylglycyl-2-(5-fuorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fuoroura-cil. J Drug Target. 2007;15:199-205.
222. Philip AK, Dubey RK, Pathak K. Optimizing delivery of furbiprofen to the colon using a targeted prodrug approach. J Pharm Pharmacol. 2008;60:607-613.
223. Cassano R, Trombino S, Cilea A, Ferrarelli T, Muzzalupo R, Picci N. L-lysine pro-prodrug containing trans-ferulic acid for 5-amino salicylic acid colon delivery: synthesis, characterization and in vitro antioxidant activity evaluation. Chem Pharm Bull. 2010;58:103-105.
224. Saenger W. Cyclodextrin inclusion compounds in research and industry. Angew Chem Int Ed Engl. 1980;19:344-362.
225. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res. 1997;14:556-567.
226. Flourie B, Molis C, Achour L, Dupas H, Hatat C, Rambaud JC. Fate of β-cyclodextrins in the human intestine. J Nutr. 1993;123:676-680.
227. Uekama K, Minami K, Hirayama F. 6A-O-[(4-Biphenylyl)acetyl]-α-, -β-, and -γ-cyclodextrins and 6A-Deoxy-6A-[[(4-biphenylyl)acetyl]amino]-α-, -β-, and -γ-cyclodextrins: Potential Prodrugs for Colon-Specific Delivery. Potential prodrugs for colon specifc delivery. J Med Chem. 1997;40:2755-2761.
228. Minami K, Hirayama F, Uekama K. Colon specific drug delivery based on cyclodextrin prodrug: Release behaviour of biphenylyl acetic acid from its cyclodextrin conjugates in rat intestinal tract after oral administration. J Pharm Sci. 1998;87:715-720.
229. Hirayama F, Minami K, Uekama K. In vitro evaluation of biphenylyl acetic acidbetacy-clodextrin conjugates as colon-targeting prodrugs: drug release behaviour in rat biological media. J Pharm Pharmacol. 1996;48:27-31.
230. Zou M, Okamoto H, Cheng G, Hao X, Sun J, Cui F, Danjo K. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specifc delivery systems. Eur J Pharm Biopharm. 2005;59:155-160.
231. Zou MJ, Cheng G, Okamoto H, Hao XH, An F, Cui FD, Danjo K. Colon-specifc drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J Gastroenterol. 2005;11:7457-7460.
232. El-Kamel AH, Abdel-Aziz AA, Fatani AJ, El-Subbagh HI. Oral colon targeted delivery systems for treatment of infammatory bowel diseases: Synthesis, in vitro and in vivo assessment. Int J Pharm. 2008;358:248-255.
233. Hultin E, Nordstrom L. Investigations on dextranase. I. On the occurrence and the assay of dextranase. Acta Chem Scand. 1949;3:1405-1417.
234. Sery TW, Hehre EJ. Degradation of dextrans by enzymes of intestinal bacteria. J Bacteriol. 1956;71:373-380.
235. Rosenfeld EL, Lukomskaya IS. The splitting of dextran and isomaltose by animal tissues. Clin Chim Acta. 1957;2:105-113.
236. Hehre EJ, Sery TW. Dextran-splitting anaerobic bacteria from the human intestine. J Bac-teriol. 1952;63:424-426.
237. Harboe E, Larsen C, Johansen J. Macromolecular prodrug. X. Bioavailability of naproxen after oral administration of dextran-naproxen ester conjugates in rabbits. Farmaci Sci Ed. 1988;16:65-72.
238. Inoue M, Morikawa M, Tsuboi M, Yamada T, Sogiura M. Hydrolysis of ester type drugs by the purifed esterases from human intestinal mucosa. Int J Pharm. 1979;29:17-21.
239. Harboe E, Johansen M, Larsen C. Macromolecular prodrugs. VI coupling of the highly lipophilic agent naproxen to dextran and in vitro characterization of the conjugates. Farmaci Sci Ed. 1988;16:73-85.
240. Larsen C, Harboe E, Johansen M, Olesen HP. Macromolecular prodrugs. XVI. Colon targeted delivery. Comparison of the rate of release of naproxen from dextran ester prodrugs in homo-genates of various segments of the pig gastrointestinal tract. Pharm Res. 1989;6:995-999.
241. Harboe E, Larsen C, Johansen M, Olesen HP. Macromolecular prodrug. XIV. Absorption characteristics of naproxen after oral administration of dextran T-70-naproxen ester prodrug in pigs. Int J Pharm. 1989;53:157-165.
242. Harboe E, Larsen C, Johansen M, Olesen HP. Macromolecular prodrug. XV. Colon-targeted delivery-bioavailability of naproxen from orally administered dextran-naproxen ester pro-drugs varying in molecular size in the pig. Pharm Res. 1989;6:919-923.
243. McLeod AD, Tolentino L, Tozer TN. Glucocorticoid-dextran conjugates as potential pro-drugs for colon-specifc delivery: steady-state pharmacokinetics in the rat. Biopharm Drug Dispos. 1994;15:151-161.
244. McLeod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugate as potential prodrug for colon-specifc delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci. 1994;83:1284-1288.
245. McLeod AD, Friend DR, Tozer TN. Synthesis and chemical stability of glucocorticoid-dex-tran esters: potential prodrugs for colon-specifc delivery. Int J Pharm. 1993;92:105-114.
246. Shavej A, Tester RF, Corbett A, Karkalas J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr Res. 2006;341:2694-2701.
247. Basan H, Gümüşderelioǧlu M, Orbey MT. Release characteristics of salmon calcitonin from dextran hydrogels for colon-specifc delivery. Eur J Pharm Biopharm. 2007;65:39-46.
248. Pitarresi G, Casadei MA, Mandracchia D, Paolicelli P, Palumbo FS, Giammona G. Pho-tocrosslinking of dextran and polyaspartamide derivatives: A combination suitable for colon-specifc drug delivery. J Controlled Rel. 2007;119:328-338.
249. Feeney M, Giannuzzo M, Paolicelli P, Casadei MA. Hydrogels of dextran containing non-steroidal anti-infammatory drugs as pendant agents. Drug Deliv. 2007;14:87-93.
250. Varshosaz J, Emami J, Tavakoli N, Fassihi A, Minaiyan M, Ahmadi F, Dorkoosh F. Synthesis and evaluation of dextran-budesonide conjugates as colon specifc prodrugs for treatment of ulcerative colitis. Int J Pharm. 2009;365:69-76.
251. Varshosaz J, Emami J, Ahmadi F, Tavakoli N, Minaiyan M, Fassihi A, Mahzouni P, Dor-koosh F. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis. J Drug Target. 2011;19:140-153.
252. Casadei MA, Pitarresi G, Calabrese R, Paolicelli P, Giammona G. Biodegradable and pH-sensitive hydrogels for potential colon-specifc drug delivery: characterization and in vitro release studies. Biomacromolecules. 2008;9:43-49.
253. Kim IH, Kong HS, Choi BI, Kim YS, Kim HJ, Yang YW, Jung YJ, Kim YM. Synthesis and in vitro properties of dexamethasone 21-sulfate sodium as a colon-specifc prodrug of dexamethasone. Drug Dev Ind Pharm. 2006;32:389-397.
254. Kim I, Kong H, Lee Y, Hong S, Han J, Jung S, Jung Y, Kim YM. Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifcally delivering the steroid to the large intestine. Pharm Res. 2009;26:415-421.
255. Doh MJ, Jung YJ, Kim I, Kong HS, Kim YM. Synthesis and in vitro properties of pred-nisolone 21-sulfate sodium as a colon-specifc prodrug of prednisolone. Arch Pharm Res. 2003;26:258-263.
256. Kong H, Kim Y, Lee Y, Choi B, Jung S, Jung Y, Kim YM. Sulfate-conjugated methylpred-nisolone: evaluation as a colon-specifc methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone. J Drug Target. 2009;17:159-167.
257. Kong H, Lee Y, Hong S, Han J, Choi B, Jung Y, Kim YM. Sulfate-conjugated methyl-prednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis. J Drug Target. 2009;17:450-458.
258. Englyst HN, Hay S, Macfarlane GT. Polysaccharide breakdown by mixed populations of human fecal bacteria. FEMS Microbiol Ecol. 1987;95:163-171.
259. Pownall HJ, Hickson DL, Smith LC. Transport of biological lipophils: effect of lipophilic structure. J Am Chem Soc. 1983;105:2440-2445.
260. Conchie J, Macleod DC. Glycosidase in the mammalian alimentary canal. Nature. 1959;184:1233.
261. Rubinstein A. Approaches and opportunities in colon-specifc drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12:101-149.
262. Kobashi K, Nishimura T, Kusaka M, Hattori M, Namba T. Metabolism of sennosides by human intestinal bacteria. Planta Medica (J Med Plant Res). 1980;40:225-236.
263. Friend DR, Chang GW. A colon-specifc drug delivery system based on drug glycosides and glycosidase of colonic bacteria. J Med Chem. 1984;27:261-266.
264. Friend DR, Chang GW. Drug glycosides: Potential prodrugs for colon specific drug delivery. J Med Chem. 1985;28:51-57.
265. Friend DR, Phillips S, McLeod A, Tozer TN. Relative inflammatory effect of oral dexamethasone-β-D-glucoside and dexamethasone in experimental inflammatory bowel disease in guinea pig. J Pharm Pharmacol. 1991;43:353-355.
266. Friend DR, Tozer TN. Drug glycosides in oral colon-specific drug delivery. J Controlled Rel. 1992;19:109-120.
267. Tozer TN, Rigod J, McLeod AD, Gungon R, Hoag MK, Friend DR. Colon-specifc delivery of dexamethasone from a glucoside prodrug in the guinea pig. Pharm Res. 1991;8:445-454.
268. Scheline RR. Drug metabolism by intestinal microorganism. J Pharm Sci. 1968;57:2021-2037.
269. Simpkins JW, Smulkowski M, Dixon R, Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther. 1988;244:195-205.
270. Haeberlin B, Rubas W, Nolen HW 3rd, Friend DR. In vitro evaluation of dexamethasone-β-D-glucuronide for colon-specific drug delivery. Pharm Res. 1993;10:1553-1562.
271. Fedorak RN, Cui N, Friend DR, Madsen KL, Empey LR. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am J Physiol Gastrointest Liver Physiol. 1995;269:G210-G218.
272. Cui N, Friend DR, Fedora RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut. 1994;35:1439-1446.
273. Nolen HW 3rd, Fedorak RN, Friend DR. Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. Biopharm. Drug Dispos. 1997;18:681-695.
274. Nolen HW, Friend DR. Menthol-β-D-glucuronide: A potential prodrug for treatment of the irritable bowel syndrome. Pharm Res. 1994;11:1707-1711.
275. Pillay V, Fassihi R. Unconventional dissolution methodologies. J Pharm Sci. 1999;88:843-851.
276. Khan MZ, Prebeg Z, Kurjaković N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Controlled Rel. 1999;58:215-222.
277. Takeuchi H, Yasuji T, Yamamoto H, Kawashima Y. Spray-dried lactose composite particles containing an ion complex of alginate-chitosan for designing a drycoated tablet having a time-controlled releasing function. Pharm Res. 2000;17:94-99.
278. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated timed-release presscoated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm. 2000;204:7-15.
279. Rudolph MW, Klein S, Beckert TE, Peetereit HU, Dressman JB. A new 5-aminosalicylic acid multiunit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001;51:183-190.
280. Wong D, Larrabeo S, Clifford K, Tremblay J, Friend DR. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulation. J. Controlled Rel. 1997;47:173-179.
281. Debongnie JC, Phillips SF. Capacity of the human colon to absorb fluid. Gastroenterology. 1978;74:698-703.
282. Wingins HS, Cummings JH. Evidence for the mixing of residue in the human. Gut. 1976;17: 1007-1011.
283. Siew LF, Basit AW, Newton JM. The potential of organic based amylose ethylcellulose flm coatings as oral colon-specifc drug delivery systems. AAPS PharmSciTech. 2000;1:53-61.
284. Siew LF, Man SM, Newton JM, Basit AW. Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro. Int J Pharm. 2004;273:129-134.
285. Leong CW, Newton JM, Basit AW, Podczeck F, Cummings JH, Ring SG. The formation of colonic digestible flms of amylose and ethylcellulose from aqueous dispersions at temperatures below 37 degrees C. Eur J Pharm Biopharm. 2002;54:291-297.
286. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier. Pharm Res. 1993;10;258-263.
287. Jung YJ, Lee JS, Kim YM. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-gly-cine as a colon-specifc prodrug of 5-aminosalicylic acid. J Pharm Sci. 2000;89:594-602.
288. Rama Prasad YV, Krishnaiah YS, Satyanarayana S. In vitro evaluation of guar gum as a carrier for colon-specifc drug delivery. J Controlled Rel. 1998;51:281-287.
289. Krishnaiah YS, Bhaskar Reddy PR, Satyanarayana V, Karthikeyan RS. Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int J Pharm. 2002;236:43-55.
290. Molly K, Vande Woestyne M, Verstraete W. Development of a five-step multichamber reactor as a simulation of the human intestinal microbial ecosystem. Appl Microbiol Biotechnol. 1993;39:254-258.
291. Schacht E, Gevaert A, Refaie EI, Kenawy MKW, Verstraete W, Adriaensens P, Carleer R, Gelan J. Polymers for colon-specific drug delivery. J Controlled Rel. 1996;39:327-338.
292. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C. Long-term weekly treatment of colorectal metastatic cancer with fuorouracil and leucovorin: results of amulticentric prospective trial of fuorouracil dosage optimization by pharmaco-kinetic monitoring in 152 patients. J Clin Oncol. 1998;16:1470-1478.
293. Yang L. Biorelevant dissolution testing of colon-specifc delivery systems activated by colonic microfora. J Controlled Rel. 2008;125:77-86.
294. Salyers AA, Leedle JA. Carbohydrate metabolism in the human colon. In: Hentge DJ, editor. Human Intestinal Microfora in Health and Disease. New York: Academic Press; 1983. p.129-146.
295. Yu CY, Yin BC, Zhang W, Cheng SX, Zhang XZ, Zhuo RX. Composite microparticle drug delivery systems based on chitosan, alginate and pectin with improved pH-sensitive drug release property. Colloids Surf B Biointerfaces. 2009;68:245-249.
296. Van den Mooter G, Samyn C, Kinget R. In vivo evaluation of a colon-specifc drug delivery system: an absorption study of theophylline from capsules coated with azo polymers in rats. Pharm Res. 1995;12:244-247.
297. Tozaki H, Nishioka J, Komoike J, Okada N, Fujita T, Muranishi S, Kim SI, Terashima H, Yamamoto A. Enhanced absorption of Insulin and (Asu1,7)eel-calcitonin using novel azaopolymer-coated pellets for colon-specific drug delivery. J Pharm Sci. 2001;90:89-97.
298. Omar S, Aldosari B, Refai H, Gohary OA. Colon-specific drug delivery for mebeverine hydrochloride. J Drug Target. 2007;15:691-700.
299. Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. Time and pH dependent colon specifc, pulsatile delivery of theophylline for nocturnal asthma. Int J Pharm. 2007;328:49-56.
300. Patel MM, Amin AF. Design and optimization of colon targeted system of theophylline for chronotherapy of nocturnal asthma. J Pharm Sci. 2011;100:1760-72.
301. Patel MM, Amin AF. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. Drug Deliv. 2011;18:281-93.
302. Patel MM, Amin AF. Process, optimization and characterization of mebeverine hydrochlo-ride loaded guar gum microspheres for irritable bowel syndrome. Carbohydr Polym. 2011;86:536-545.
303. Saffran M, Field JB, Pena J, Jones RH, Okuda Y. Oral insulin in diabetic dogs. J Endocrinol. 1991;131:267-278.
304. Takaya T, Ikeda C, Imagawa N, Niwa K, Takada K. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. J Pharm Pharmacol. 1995;47:474-478.
305. Shibata N, Obno T, Shimokawa T, Hu Z, Yoshikawa Y, Koga K, Murakami M, Takada K. Application of pressure-controlled colon delivery capsule to oral administration of glycyr-rhizin in dogs. J Pharm Pharmacol. 2001;53:441-447.
306. Fan LF, He W, Bai M, Du Q, Xiang B, Chang YZ, Cao DY. Biphasic drug release: permeability and swelling of pectin/ethylcellulose flms, and in vitro and in vivo correlation of flm-coated pellets in dogs. Chem Pharm Bull. 2008;56:1118-1125.
307. Karali TT. Comparison of the gastrointestinal anatomy, physiology and biochemistry of human and commonly used laboratory animals. Biopharm Drug Dispos. 1995;16:351-380.
308. Watt J, Marcus R. Carrageenan-induced ulceration of large intestine in the guinea pig. Gut. 1971;12:164-171.
309. Renwick AG. First-pass metabolism within the lumen of the gastrointestinal tract. In: Gorge CF, Shand G, Renwick AG, editors. Clinical Pharmacology and Therapeutics, Presystemic Drug Elimination. London: Butterworth Scientifc; 1982. p. 3-28.
310. Adkin AD, Kenyon CJ, Lerner EI, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR. The use of scintigraphy to provide 'proof of concept' for novel polysaccharide preparation designed for colonic drug delivery. Pharm Res. 1997;14:103-107.
311. Gliko-Kabir I, Yagen B, Baluom M, Rubinstein A. Phosphated crosslinked guar for colon-specifc drug delivery. II. In vitro and in vivo evaluation in the rat. J Controlled Rel. 2000;63:129-134.
312. Percy WH, Burton MB, Fallick F, Burakoff R. A comparison in vitro of human and rabbit distal colonic muscle responses to inflammatory mediators. Gastroenterology. 1990;99:1324-1332.
313. Katsuma M. Colon-specifc drug delivery system (CODESTM). Fifth US-Japan Symposium on Drug Delivery Systems; 1999 December 12-17; Lahaina, Hawaii.
314. Davis SS, Wilding EA, Wilding IR. Gastrointestinal transit of a matrix tablet formulation: comparison of canine and human data. Int J Pharm. 1993;94:235-238.
315. Hu Z, Shimokawa T, Ohno T, Kimura G, Mawatari S, Kamitsnna M, Yoshikawa Y, Masuda S, Takada K. Characterization of norfoxacine release from tablets coated with a new pH-sensitive polymer, P-4135F. J Drug Target. 1999;7:223-232.
316. Lee WW, Wilson CG, Mukherji G. Time-dependent systems for colonic delivery. In: Rath-bone MJ, Hadgraft J, Roberts MS, editors. Modifed-release drug delivery technology. New York: Marcel Dekker; 2003. p. 243-248.
317. Alpsten M, Ekenved G, Soelvell L. A profile scanning method of studying the release properties of different types of tablets in man. Acta Pharm Suec. 1976;13:107-122.
318. Casey DL, Beihn RM, Digenis GA, Shambu MB. Method for minitoring hard gelatin capsule disintegration times in human using external scintigraphy. J Pharm Sci. 1976;65:1412-1413.
319. Digenis GA, Sandefer E. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit Rev Ther Drug Carrier Syst. 1991;7:309-345.
320. Wilding IR, Coupe AJ, Davis SS. The role of γ-scintigraphy in oral drug delivery. Adv Drug Deliv Rev. 1991;7:87-117.
321. Newman SP, Wilding IR. Imaging techniques for assessing drug delivery in man. Pharm Sci Tech Today. 1999;2:269-288.
322. Takemura S, Watanabe S, Katsuma M, Fukui M. Human Gastrointestinal transit study of a novel colon delivery system (CODES™) using γ-scintigraphy. Proceedings of the International Symposium on Controlled Release of Bioactive Materials; 2000 July 11-13; Paris, France.
323. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27:886-892.
324. Pai CM, Lim CB, Lee SJ, Park I, Seomoon G, Connor AL, Wilding IR. Pharmacoscin-tigraphic and pharmacokinetic evaluation of colon specifc delivery system in healthy volunteers. Proceedings of the International Symposium on Controlled Release of Bio-active Materials; 2000 July 11-13; Paris, France.
325. Ibekwe VC, Khela MK, Evans DF, Basit AW. A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology. Aliment Pharmacol Ther. 2008;28:911-916.
326. Krishnaiah YSR, Satyanarayana S. Colon specific drug delivery. In: Jain NK, editor. Advances in controlled and novel drug delivery. New Delhi: CBS Publications and Distributors; 2006. p. 89-119.